药物遗传学 hSLCO1B1*14 - - 在转基因关节炎小鼠中以甲索特酸为导向的剂量使暴露和反应正常化
Felicia Gooden1,2, Brennan D Meier3, Griffin D Shaffer1,2
1Department of Pharmacology, Physiology, and Neurobiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Clinical and translational science
|December 25, 2025
概括
患有SLCO1B1*14等位基因的青少年异常性关节炎患者显示甲状腺素清除率增加. 基于药理遗传学的个性化剂量可以提高JIA中甲状腺素的疗效和耐受性.
科学领域:
- 药物基因组学 药物基因组学
- 免疫学 免疫学 免疫学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 青春期异常性关节炎 (JIA) 影响到美国约10万名儿童,其中约30%的孩子未能接受甲状腺素治疗.
- 这种SLCO1B1*14等位基因与增加MTX清除,减少暴露和JIA患者的无反应有关.
- 了解MTX药理动力学的遗传影响对于优化JIA治疗至关重要.
研究的目的:
- 研究SLCO1B1*14等位基因对JIA小鼠模型中MTX反应的影响.
- 评估药物遗传学导向剂量的潜力,以提高MTX在JIA中的疗效.
主要方法:
- 产生了表达人类SLCO1B1*14和控制hSLCO1B1*1等位基因的转基因小鼠,mSlco1b2被淘汰.
- 利用原诱导的关节炎模型来评估对MTX的关节炎反应.
- 采用基于质谱的蛋白质组学和药物动力学建模来分析OATP1B1丰度和MTX暴露.
主要成果:
- 与hSLCO1B1*1小鼠相比,hSLCO1B1*1小鼠的OATP1B1蛋白丰度高出2.1倍.
- 在hSLCO1B1*14小鼠中,使用1mg/kgMTX治疗导致疾病负担增加39%,MTXAUC降低22%.
- 药物动力学建模表明,hSLCO1B1*14小鼠需要30%的MTX剂量,以匹配hSLCO1B1*1小鼠的暴露和反应.
结论:
- 在JIA小鼠模型中,SLCO1B1*14等位基因显著增加MTX清除,并降低治疗疗效.
- 药物遗传学导向的剂量,如在SLCO1B1*14等位基因携带者中增加30%的MTX剂量,可以使MTX暴露和反应正常化.
- 这些发现支持药物遗传学测试对优化JIA患者MTX治疗的临床实用性.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
01:17Phase II Reactions: Methylation Reactions
655
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
655
02:50Dosage Compensation
7.0K
In animals, gender is determined by the number and type of sex chromosome. For example, human females have two X chromosomes, and males have one X and one Y chromosome, whereas C.elegans with one X chromosome is a male, and the one with two X chromosomes is a hermaphrodite.
In addition to sexual development, the X chromosome has genes involved in autosomal functions such as brain development and the immune system. Therefore, males and females with distinct numbers of X chromosomes will...
In addition to sexual development, the X chromosome has genes involved in autosomal functions such as brain development and the immune system. Therefore, males and females with distinct numbers of X chromosomes will...
7.0K
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
133
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
133
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
197
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
197